kreature
07 Apr 2016
tosh I see Tosh appears to have been removed from LSE. Should make for a particularly boring forum
kipngail
06 Apr 2016
Alternative OR 'logical view' ??? Given that the GLUMS seem to be trumpeting / focusing - on the 14 million 'purchase' { As per the latest 'placing'.... by Calculus {{{ there MUST also....the maths tell *US* that .... be OTHER II sources of funding / participant II's }}}Let *US* ponder =The last time II's were 'invited' to 'invest' large funds - to keep the lights on - WAS at "an out of the blue" price of 22p. Which, of course - the 'invited' II's DID.NO ONE should dream that the 'invited' II's had no previous 'input' as to setting the price at 22p..Given all the trHYPE since the 22p 'placing'..... one might 'expect the S P to go / have gone 'up'..SO =Why do *WE* think / What can be learned, from the FACT that, these same 'invited' II's are now "HAPPY" to 'protect their 'investment' at 17p ???.OR, are these II's - simply 'topping up' ??? { Something that II's DO NOT DO }It should be remembered that , Calculus have a 'seat on the BoD'.Locic would tell shareholders that, 22p >>>>17p is NOT what they might expectTheir fundholders might be "HAPPIER" {As would *WE* ALL } with 17p >>>22p..Can ANYONE { other than the lunatic TRANCE} call this 'progress' ???
kipngail
04 Apr 2016
Great sport { MFFF } Most amusing to watch how the TRANCE re-act.How come Larry, Mo and Curly { The 3 most inept MEMBERS } ALWAYS feel the NEED to 'rush' to be first to 'defend' the trHYPE 'One view ONLY' dictate ??? .... ALWAYS, in the most feeble manner.NO WONDER the trHYPE is now 'manifestly ignored'.G F seems to be a 'popular' response, by the REAL investing world.
kreature
04 Apr 2016
oo so 1m short? oo subscribers shafted, already below 17p? How short of funds are they to conduct the next trial and complete the never-ending existing trial?
kipngail
04 Apr 2016
Just as a matter of interest Has anyone been able to / or ACTUALLY bought any shares here BELOW the OO price of 17p ?*WE* know there were some who were 'happy' to be buying at HIGHER prices prior to the 'long awaited OO'.... however, the only 'trades' recently BELOW the OO price, appear to be sells ??? STRANGE trading tactics some people adopt ??? .... but there you go.On a 'broader front, the TRANCE seem to be 'sure' that *WE* can expect plenty of 'news' in the near future, which, judging by the trHYPERS track record to date, is generally a sign that there will be NONE.After YEARS of a FLOOD of 'broken promise' assurances of 'GLUM Jam tomorrow' failuresSurelee -They must get something RIGHT..... one day ???{Best not hold your breath though }
loper
01 Apr 2016
Scancell well ahead of the game here. From PIVAC 0ctober 2015Antigenicity and immunogenicity of humantumors.Pierre G. Coulie, David Schröder,Orian Bricard,, Gérald Hames,, Nathalie Rémy,Tiphanie Gomard, Javier Carrasco de Duve Institute, Brussels, BELGIUM, 2 GrandHôpital de Charleroi, Charleroi, BELGIUMMost human tumors bear antigens that can berecognized by T cells. Some of these antigens,notably those encoded by genes that aremutated in the tumor, are truly tumor-specific andT cells naturally obtained against them do notdamage normal tissues. Such ‘mutated’ antigensrecognized by T cells were first described on themouse mastocytoma cells P815 and, exactly20 years ago, mutated antigens were foundto be present also on human tumors, namelymelanomas. Mutated antigens were repeatedlyidentified on human tumors of different types.Most of them are unique and result fromsingle nucleotide substitutions. Their absolutetumor-specificity qualified them to (re)stimulateantitumor T cells in patients but their identificationwas laborious. Today they are back on centerstage as they appear to be a key determinantto the clinical success of immunostimulatoryantibodies. Patients with a tumor containingmany candidate ‘antigenic’ mutations, i.e. nonsynonymousin an HLA-binding peptide, aremore susceptible to display a clinical response toanti-CTLA-4 or anti-PD-1 antibodies.Most if not all tumors are antigenic. In additionmany of them are immunogenic: they naturallyprime tumor-specific T cells in vivo. The bestexample, and certainly the best studied,is melanoma. We are currently exploringprimary breast carcinomas. The importance ofspontaneous antitumor T cell responses priorto immunotherapy with immunostimulatoryantibodies is yet to be explored and might varywith the targeted inhibitory or costimulatorypathway.It is a tautology that in patients tumors progressdespite their antigenicity and immunogenicity.They are automatically selected for variants thatescape or blunt immune attack. Immunotherapyshould therefore be used as early as possibleand include compounds that counteractintratumoral immunosuppression.
kipngail
01 Apr 2016
The 'maths' appear 2 B a 'problem' Mother F***er Fallout Forum ..... AGAIN.Boomorbust .... {Who SHOULD know BETTER }View Thread (5)RoddyToday 07:37Where do you get a £1.1 shortfall from?They planned to raise £6.8 million and raised £6.1 not a blinding result but not bad at all in the current climate for biotechs. and given the EIS/HMRC on the largest institutional investors.Dear oh dear... IF one reads the latest RNS, one would SEE that IN FACT it states CLEARLY that Scancell - HOPED to raise =£3.4 million.... via PLACING = { fully taken up }£ 3.8 million..... via OPEN OFFER = { NOT fully taken up }.TOTAL = £7.2 million...... NOT £6.8 millionAmount ACTUALLY raised = £6.1 million= A 'shortfall of £1.1 million{ An ACTUAL shortfall... that the trHYPERS TRANCE insisted WAS NOT "On the cards" }.IF ONLY certain people would put in as much EFFORT to discussing FACTS, as they do in 'supporting' FICTIONS.... then sentiment for this 'investment' MIGHT improve.
Ripley94
01 Apr 2016
Re: Fund raising result No scale back ... you might by @ 17 but it will cost you !!
kipngail
01 Apr 2016
What CAN *WE* learn ??? "The TRANCE' insisted this { P I offer } would - without doubt - be OVER subscribedThe ASTUTE were NOT so easily fooled by their trHYPE, and indeed observed that, this MIGHT well be UNDER subscribed { Pointing out the 'timing' of events = less than one week after R G stated { on camera } that ... "We have enough money to last out / for THIS YEAR"REALITY =UNDER subscribed.Now *WE* witness certain GLUMS trying to 'cover their tracks' by CLAIMING that THEY { The trHYPERS } themselves - DID NOT participate { Whilst urging others to 'cough-up' } solely due to the fact that - they, the trHYPERS, were, { As were Scancell }...... "Stapped for cash" ???.EVIDENCE, if more is needed, as to the DANGERS of 'disregarding' the ALTERNATIVE views, which AGAIN = proved to be RIGHT..So, are *WE* about to see the FLOOD of BUY, BUY, BUYing that the TRANCE say *WE* should 'expect' ???ORWill recent events make 'investors' EVEN more CAUTIOUS .Lindy does NOT deserve this 'smambles'Lindy deserves MUCH BETTER.
Aimbig
01 Apr 2016
OO Failure Investors are becoming more ASTUTE. Why buy at 17p through an OO when you can wait and buy for less on the open market.Only the Fools on LSE are stupid enough to participate although I suspect we will see many denying they took up the OO when they see the SP continue its decline.A Fool and his money...........
biotech billy
01 Apr 2016
Re: Fund raising result I doubt that a scale back would have been applied in view of the relatively poor take-up overall.BB
Ripley94
01 Apr 2016
Re: Fund raising result BillyDo you know if there was a scale back for those who applied for more ?
biotech billy
01 Apr 2016
Fund raising result Although the institutional offer was fully subscribed, only 71% of shares on offer were taken up by existing shareholders. Disappointing. The amount of money raised is not even for the trials next year, it is for ongoing funding for the company and finances for the preparation of the trials. I really do think that we need a big pharma to buy out the company. Going it alone is beginning to look unrealistic. Unfortunately I think that the reluctance of companies to buy Scancell is due to the fact that the SCIB1 trial is not double-blinded, and with very small numbers of patients.BB
kipngail
31 Mar 2016
Another 'Let down' ??? Weren't the 'Trance' expecting / predicting the 'usual' revalations and wondrous RNS's , which would be bound to 'erupt' from the latest 'CON ference' ???As per the 'norm', the latest 'CON ference' ... along with ALL the previous 'marvellous opportunities' which the 'Trance' would have everyone believe MUST provide 'the breakthrough' .... has, to date, provided ---- ALLDoes anyone know when the next one is 'scheduled' ???It will, no doubt, be heralded by the 'Trance', in the SAME way as ALL the previous ones, as ... 'The breakthrough'
Aimbig
30 Mar 2016
Is it still below £1? Surely not. After years of TrHype, it must have at least touched the minted figure.The only thing Scancell has touched is the lights out switch.Going down faster than Elsie on Rats.
